Cat.No. : CSC-RO0586 Host Cell: Jurkat
| Cat. No. | CSC-RO0586 |
| Description | This cell line is derived from Jurkat and is engineered to stably overexpress Human TIGIT. |
| Gene | TIGIT |
| Gene Species | Homo sapiens (Human) |
| Host Cell | Jurkat |
| Host Cell Species | Homo sapiens (Human) |
| Stability | Validated for at least 10 passages |
| Application | 1. Studying the interactions between immune cells and cancer cells 2. Studying the mechanisms of resistance to immune checkpoint blockade 3. High-throughput screening 4. Drug target validation |
| Quality Control | Negative for bacteria, yeast, fungi and mycoplasma. |
| Shipping | Dry ice |
| Storage | Liquid nitrogen |
| Revival | Rapidly thaw cells in a 37°C water bath. Transfer contents into a tube containing pre-warmed media. Centrifuge cells and seed into a 25 cm2 flask containing pre-warmed media. |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
Emerging immunological checkpoint molecule TIGIT (T cell immunoreceptor with Ig and ITIM domains) interacts with ligand PVR (poliovirus receptor) to promote immune tolerance and tumor escape, causing T and NK cell anergy. The scientists used in silico mutagenesis and MD simulations to study TIGIT and PVR. Their findings revealed that specific loops within PVR experienced significant intra-molecular rearrangements during the simulations, resulting in increased hydrogen bonding with TIGIT. They identified key residues for interaction and predicted several high-affinity PVR mutants (PVRS72W, PVRS72R, PVRG131V, and PVRS132Q) through biological assays on TIGIT-overexpressing Jurkat cells. These mutants demonstrated a stronger binding affinity and more potent inhibitory effects compared to the wild-type PVR.
Figure 1. The researchers investigated the biological functions of PVR mutants by transfecting human TIGIT into Jurkat cells, which do not express endogenous TIGIT. They co-cultured these Jurkat-TIGIT cells with CHO-K1 cells expressing either wild-type or mutant PVR. (Zhou X, et al., 2021)
Creative Biogene's Human TIGIT Stable Cell Line - Jurkat offers a robust platform for further research in this field, allowing researchers to explore the dynamics of TIGIT and its ligands. With stable expression, this cell line enables detailed investigations into the efficacy of novel PVR mutants and their potential therapeutic applications.
A: The TIGIT gene encodes for the TIGIT (T cell immunoglobulin and ITIM domain) protein, which is a recently discovered inhibitory receptor expressed on the surface of T cells and natural killer (NK) cells. TIGIT plays a role in regulating immune responses by inhibiting the activation and function of these immune cells. It does so by interacting with other proteins on the surface of antigen-presenting cells and T cells.
A: The TIGIT gene contributes to immune response regulation by inhibiting excessive immune activation and preventing autoimmunity. By interacting with the CD226 receptor on T cells and NK cells, TIGIT can inhibit their responses to certain antigens. This inhibition helps maintain immune tolerance and prevents the immune system from attacking healthy cells.
A: Mutations in the TIGIT gene are not commonly associated with specific diseases. However, dysregulation of TIGIT expression or function may lead to alterations in immune responses, potentially affecting the body's ability to mount effective defenses against pathogens or cancer cells.
A: The expression of the TIGIT gene is regulated by various factors, including cytokines and transcription factors. The activation of T cells and NK cells can lead to the upregulation of TIGIT expression. Additionally, regulatory mechanisms, such as epigenetic modifications and post-translational modifications, can influence the expression of TIGIT, ensuring proper immune responses.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
The Human TIGIT Stable Cell Line - Jurkat exhibits low immunogenicity, making it suitable for applications where minimal immune response is desired, such as in vitro immunological assays and drug discovery research.
The cell line undergoes rigorous sterility testing to ensure that it is free from any contaminants, providing researchers with a reliable and pure culture for their experiments without the risk of introducing unwanted microbes.
The Human TIGIT Stable Cell Line - Jurkat is derived from a human T-cell leukemia cell line, and therefore, it is important to handle it with appropriate safety measures. Researchers should be aware of the potential tumorigenic properties and follow ethical guidelines when working with this cell line.
Regular mycoplasma testing is performed on the Human TIGIT Stable Cell Line - Jurkat to ensure its integrity and prevent any potential contamination that could affect experimental results. This guarantees the reliability and consistency of the cell line for various research applications.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Copyright © Creative Biogene. All rights reserved.
